PROFILBARU.COM

Nariman Bomanshaw Mehta
Nariman Bomanshaw Mehta
	Mehta in 2008
Born	April 20, 1920; Bombay, Bombay Presidency, British India
Died	August 22, 2014 (aged 94); Burlington, North Carolina, U.S.
Nationality	American
Alma mater	St. Xavier's College, Mumbai, University of Kansas
Known for	Synthesis of antidepressant drug Bupropion (marketed as Wellbutrin)
Spouse	Barbara DeShane
Children	2 daughters, 1 son
	Scientific career
Fields	Organic chemistry
Institutions	Seagram, GlaxoSmithKline

Nariman Bomanshaw Mehta (April 20, 1920 – August 22, 2014)^[1] was an Indian-born American organic chemist and pharmacologist who designed, synthesized, and patented the organic compound bupropion, marketed under the name Wellbutrin as an antidepressant and smoking cessation aid.^[2]

Early life and education

Mehta was born in Bombay, India into a Parsi Zoroastrian family. He attended St. Xavier's College in Bombay, from where he received Bachelor of Science degrees in chemistry and physics and Bachelor of Arts degrees in English and economics, and a Master of Science degree. In 1939, he and fellow student Kaikhosrov D. Irani, later a noted academic in his own right, wrote and published a Textbook of Theoretical and Practical Physics.^[3]

Mehta won a Tata Scholarship and received a grant from Wendell Willkie. In 1947 Mehta went to the United States, where he earned a PhD in chemistry from The University of Kansas.^{[citation needed]} Mehta's 1952 dissertation was titled I. Use of the Hammett equation in the prediction of product ratios in the Schmidt reaction of unsymmetrical diarylethylenes: II. The synthesis of possible emetine intermediates.^[4]

He had two daughters and a son.^{[citation needed]}

Career

Seagram invited Mehta to the United States as a trainee in their research lab, where he learned about fermentation and distillation. During his time at Seagram, Mehta studied the antibiotic Penicillin. While teaching chemistry at Central State University, Wilberforce, Ohio, Mehta joined the pharmaceutical company Burroughs Wellcome, Inc., now GlaxoSmithKline, where he worked on potential neuropsychopharmacological drugs and designed, synthesized, and patented (in 1969) the compound Bupropion (BW 323U66) that was approved for use as an antidepressant in 1985 and sold under the trade name Wellbutrin. Another application of the drug was as a smoking cessation aid.^[5]

Selected publications

Mehta, N B (1983), "The Chemistry of Bupropion", The Journal of Clinical Psychiatry, vol. 44, no. 5 (published May 1983), pp. 56–9, PMID 6406464
David L. Musso; Nariman B. Mehta; Francis E. Soroko; Robert M. Ferris; Elizabeth B. Hollingsworth; Bernard T. Kenney (2004), "Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion", Chirality, 5 (7) (published 2004-09-21): 495–500, doi:10.1002/chir.530050704, PMID 8240925
Mehta, Nariman B; Arthur P Phillips; Florence Fu Lui; Ronald E Brooks (1960), "Maleamic and citraconamic acids, methyl esters, and imides", The Journal of Organic Chemistry, 25 (6): 1012–1015, doi:10.1021/jo01076a038

Notes

^ ^a ^b "Nariman Bomanshaw Mehta: Obituary". Times-News. Burlington, North Carolina. August 23, 2014. Retrieved November 20, 2014.
^ U.S. patent 3,819,706
^ Irani K.D. and Mehta N.B. (1942) "Theoretical and Practical Physics"
^ Mehta, Nariman Bomanshaw (1952). I. Use of the Hammett equation in the prediction of product ratios in the Schmidt reaction of unsymmetrical diarylethylenes: II. The synthesis of possible emetine intermediates (Ph.D. thesis). University of Kansas. OCLC 55019928.
^ van Setten, Henk. "1985: Want a Zyban?". The history of mental health. Retrieved 29 November 2014.

References

"Dr. Nariman B. Mehta: A scientist and a chemist". Retrieved May 24, 2014.
Schatzberg, Alan F.; Nemeroff, Charles B. (2009). The American Psychiatric Publishing Textbook of Psychopharmacology (4 ed.). American Psychiatric Publishing, Inc. p. 416. ISBN 978-1585623099.
Wilson, Brent; Paul, Panchajanya; Mehta, Sunny; Coffey, Barbara (February 2013). "Hypokalemia Secondary to Bupropion Sustained Release Overdose". Journal of Child and Adolescent Psychopharmacology. 23 (1): 57–60. doi:10.1089/cap.2013.2313. PMC 3613169. PMID 23410142.